Pfizer reported Phase 3 success for Litfulo (ritlecitinib) in active and stable nonsegmental vitiligo, delivering positive outcomes in two trials. The result reinforces Pfizer’s autoimmune dermatology strategy as it builds toward potential regulatory action and broader line extensions. The topline readout adds to a growing category of targeted oral therapies aimed at depigmenting diseases, where durability and consistent repigmentation have remained key challenges for drug development. Investors will now look for the detail level on response rates, durability, and subgroup outcomes as Pfizer prepares next steps across trial readouts and label strategy.